🔎 Trials Near Me

Home › Scleroderma › Texas

Pag-aaral pangklinika para sa Scleroderma sa Texas

12 pag-aaral para sa Scleroderma ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • at 2 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Tekton Research, Inc - West Gate Boulevard, Austin
  • Arthritis & Rheumatology Institute - Frisco, Frisco
  • The University of Texas Health Science Center at Houston, Houston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07497087

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Denison
  • GSK Investigational Site, El Paso
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Dallas
  • Nkarta Investigational Site, Houston
Nagre-recruitPhase 1/2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Arlington, Arlington
  • Artiva Investigational Site Bellaire, Bellaire
  • Artiva Investigational Site Irving, Irving
  • at 4 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06991114

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT06827977

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

  • UT Southwestern Medical Center - Department of Dermatology, Dallas
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Hanggang edad 90 · Lahat ng kasarian · Na-update May 12, 2026 · NCT01808937

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06434363

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  • Galderma Investigational Site#7096, Arlington
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 31, 2026 · NCT07047690

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 26, 2025 · NCT05989763

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

  • aTyr Investigative Site, Dallas
  • aTyr Investigative Site, Houston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2025 · NCT05892614

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.